162 related articles for article (PubMed ID: 31333153)
1. Treatment Outcomes and Adverse Events from a Standardized Multidrug-Resistant Tuberculosis Regimen in a Rural Setting in Angola.
Aznar ML; Rando Segura A; Moreno MM; Espasa M; Sulleiro E; Bocanegra C; Gil Olivas E; Eugénio AN; Zacarias A; Katimba D; Gabriel E; Mendioroz J; López García MT; Pumarola T; Tórtola MT; Molina I
Am J Trop Med Hyg; 2019 Sep; 101(3):502-509. PubMed ID: 31333153
[TBL] [Abstract][Full Text] [Related]
2. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
3. Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India.
Isaakidis P; Varghese B; Mansoor H; Cox HS; Ladomirska J; Saranchuk P; Da Silva E; Khan S; Paryani R; Udwadia Z; Migliori GB; Sotgiu G; Reid T
PLoS One; 2012; 7(7):e40781. PubMed ID: 22792406
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and risk factors of multidrug-resistant tuberculosis in Cubal, Angola: a prospective cohort study.
Aznar ML; Rando-Segura A; Moreno MM; Soley ME; Igual ES; Bocanegra C; Olivas EG; Eugénio AN; Zacarias A; Katimba D; Gabriel E; Mendioroz J; García MTL; Suñe TP; Fernández MTT; Romero IM
Int J Tuberc Lung Dis; 2019 Jan; 23(1):67-72. PubMed ID: 30674377
[TBL] [Abstract][Full Text] [Related]
5. Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Viet Nam.
Ngoc NB; Vu Dinh H; Thuy NT; Quang DV; Huyen CTT; Hoa NM; Anh NH; Dat PT; Hoa NB; Tiemersma E; Nhung NV
PLoS One; 2021; 16(9):e0255357. PubMed ID: 34492031
[TBL] [Abstract][Full Text] [Related]
6. Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis.
Muñoz-Torrico M; Caminero-Luna J; Migliori GB; D'Ambrosio L; Carrillo-Alduenda JL; Villareal-Velarde H; Torres-Cruz A; Flores-Vergara H; Martínez-Mendoza D; García-Sancho C; Centis R; Salazar-Lezama MÁ; Pérez-Padilla R
Arch Bronconeumol; 2017 May; 53(5):245-250. PubMed ID: 28089216
[TBL] [Abstract][Full Text] [Related]
7. Occurrence of adverse events in patient receiving community-based therapy for multidrug-resistant tuberculosis in Pakistan.
Javaid A; Khan MA; Jan F; Rauf M; Khan MA; Basit A; Mehreen S
Tuberk Toraks; 2018 Mar; 66(1):16-25. PubMed ID: 30020037
[TBL] [Abstract][Full Text] [Related]
8. Drug Resistance of Mycobacterium tuberculosis Complex in a Rural Setting, Angola.
Rando-Segura A; Aznar ML; Moreno MM; Espasa M; Sulleiro E; Bocanegra C; Gil E; Eugénio ANE; Escartin C; Zacarias A; Vegue J; Katimba D; Vivas MC; Gabriel E; Marina MC; Mendioroz J; López MT; Pumarola T; Molina I; Tórtola MT
Emerg Infect Dis; 2018 Mar; 24(3):569-572. PubMed ID: 29460748
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
Park S; Jo KW; Lee SD; Kim WS; Shim TS
Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
[TBL] [Abstract][Full Text] [Related]
10. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
11. Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications.
Ali MH; Alrasheedy AA; Kibuule D; Godman B; Hassali MA; Ali HMH
Expert Rev Anti Infect Ther; 2019 Nov; 17(11):927-937. PubMed ID: 31689134
[No Abstract] [Full Text] [Related]
12. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt.
Gadallah MA; Mokhtar A; Rady M; El-Moghazy E; Fawzy M; Kandil SK
J Formos Med Assoc; 2016 Nov; 115(11):997-1003. PubMed ID: 26696497
[TBL] [Abstract][Full Text] [Related]
14. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM
Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505
[TBL] [Abstract][Full Text] [Related]
15. Ambulatory-based standardized therapy for multi-drug resistant tuberculosis: experience from Nepal, 2005-2006.
Malla P; Kanitz EE; Akhtar M; Falzon D; Feldmann K; Gunneberg C; Jha SS; Maharjan B; Prasai MK; Shrestha B; Verma SC; Zignol M
PLoS One; 2009 Dec; 4(12):e8313. PubMed ID: 20041140
[TBL] [Abstract][Full Text] [Related]
16. Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis.
Prasad R; Singh A; Srivastava R; Hosmane GB; Kushwaha RA; Jain A
Indian J Tuberc; 2016 Apr; 63(2):106-14. PubMed ID: 27451820
[TBL] [Abstract][Full Text] [Related]
17. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
[TBL] [Abstract][Full Text] [Related]
18. Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients.
Atif M; Bashir A; Ahmad N; Fatima RK; Saba S; Scahill S
BMC Infect Dis; 2017 Sep; 17(1):655. PubMed ID: 28962599
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus infection: a challenge in the complex management of two cases of multidrug-resistant tuberculosis.
Musso M; Mosti S; Gualano G; Mencarini P; Urso R; Ghirga P; Rianda A; Del Nonno F; Goletti D; Palmieri F
BMC Infect Dis; 2019 Oct; 19(1):882. PubMed ID: 31640579
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China.
Xu C; Pang Y; Li R; Ruan Y; Wang L; Chen M; Zhang H
J Infect; 2018 Apr; 76(4):348-353. PubMed ID: 29374587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
